Our technology
We start from a validated antibody.
A clinical scaffold: already humanised, already screened for liabilities.
- Clinically validated
- Already screened for liabilities
- Humanized from the start
CDR loops are designed informed by target structure.
- AntigenYour target
- The epitope is specified, not random.
- Aggregation designed out
- Polyspecificity designed out
- Glycosylation designed out
From your antigen to ranked candidates
Your antigen
Sequence or structure
Your epitope
Specified, not random
De novo CDR design
Loops that grip your target
Developability filters
Computed before synthesis
- CDR loop length
- Hydrophobic surface
- Positive charge
- Negative charge
- VH–VL charge
Ranked candidates
Best ones to the wet lab
Illustrated with PDB 1MEL.
The risk is already in the sequence.
The risk can be read before anything is made. Raybould et al., PNAS, 2019
Without us
When developability issues show up, you have two choices. First is to push forward with impurities, low productivity, difficulties. Second is to go back to an engineering cycle — 6–9 months, €1–3M. A sequence change voids the cell line. Estimate, A. Bernard, advisor.
- Generation
- Cell line
- Scale-up — the problem shows
- Scale-up & preclinicalYour side
12–16 months from DNA to IND. Xu et al., mAbs, 2022
With Immunochem
- Generation and developabilityImmunochem
- Cell lineYour side
- Scale-up & preclinicalYour side
EVOBodies™ precisely designs your antibody with developability constraints, to give you the highest chances of success in the following stages.
Your IND gets a head start: you enter cell line development sooner, and with de-risked molecules.
Our six services
- Nanobody discovery
We design VHH nanobodies against the epitope you choose, from your antigen sequence
- Antibody discovery
Conventional antibody discovery by computational design: IgG, Fab or scFv against a chosen epitope
- Antibody humanization
We humanise antibodies and nanobodies by computational design
- Miniprotein binder design
De novo miniprotein binders and minibinders designed against a chosen epitope
- Peptide discovery
Designed peptides against a chosen epitope: the smallest modality we build
- Affinity maturation
Improve affinity by design, without a display campaign.
Start designing better antibodies
We design developable antibodies using AI in under 6 weeks, wet-lab validated in 9 weeks, from your antigen sequence. No immunisation, no phage display, no animal.